Novo Nordisk's CEO said on Wednesday side-effects were not a problem in the trial of its next-generation obesity drug ...

KEY TAKEAWAYS Novo Nordisk's U.S.-listed shares are rising 4% in premarket trading after the Ozempic and Wegovy maker's ...

While Wegovy (semaglutide) sales more than doubled to DKK 19.87 billion ($2.78 billion) in the three-month period, that was slightly below estimates and Novo Nordisk said is now anticipating ...

Novo Nordisk, a leading biopharmaceutical company, is asserting confidence in its next-generation obesity drug candidate, CagriSema, despite recent concerns over trial results. The company's CEO ...

Novo Nordisk reports 26% sales growth in 2024, but projects lower 2025 growth of 16-24%. Full-year Wegovy sales up 86%, ...